Levosimendan Lyophilized Injection is a cardiovascular drug used in the management of acute decompensated heart failure. It is prepared as a lyophilized (freeze-dried) powder that requires reconstitution before administration, usually as an intravenous infusion under hospital supervision.

Here are the key details:

1. Composition and Form:

• Active ingredient: Levosimendan.

• Supplied as sterile lyophilized powder in vials.

• Reconstituted with a suitable diluent and further diluted before IV infusion.

2. Mechanism of Action:

• Calcium sensitizer: Increases the sensitivity of cardiac muscle fibers to calcium, enhancing contractility without significantly increasing oxygen demand.

• Potassium channel opener (vasodilator): Opens ATP-sensitive potassium channels in vascular smooth muscle, causing vasodilation, reducing preload and afterload.

• Together, these effects improve cardiac output and relieve symptoms of heart failure.

3. Indications:

• Short-term treatment of acute decompensated severe chronic heart failure when conventional therapy is insufficient.

• Used in intensive care or hospital settings under continuous monitoring.

4. Administration:

• Given as an IV infusion, often starting with a loading dose followed by continuous infusion.

• Duration usually ranges from 24 to 48 hours.

• Requires ECG and hemodynamic monitoring during administration.

5. Side Effects:

• Common: headache, hypotension, tachycardia, dizziness, nausea.

• May cause arrhythmias, atrial fibrillation, or hypokalemia.

• Rare but serious: severe hypotension or myocardial ischemia.

6. Contraindications:

• Severe hypotension or tachycardia at baseline.

• Significant renal or hepatic impairment.

• History of torsades de pointes or serious ventricular arrhythmias.

• Obstructive cardiac conditions (e.g., hypertrophic cardiomyopathy with obstruction).

7. Precautions:

• Continuous monitoring of blood pressure, heart rhythm, and electrolytes during infusion.

• Caution in patients with coronary artery disease, electrolyte imbalances, or risk of arrhythmias.

• Not intended for long-term maintenance therapy—used only in acute settings.

8. Storage:

• Store vials in a cool, dry place, protected from light.

• Reconstituted and diluted solutions should be used within the recommended stability period.